| Literature DB >> 30352066 |
Jan-Oliver Neumann1, Benito Campos2, Bilal Younes2, Martin Jakobs1, Christine Jungk1, Christopher Beynon2, Andreas von Deimling3, Andreas Unterberg2, Karl Kiening1.
Abstract
BACKGROUND: Frame-based stereotactic biopsy (FBSB) is a minimally-invasive and effective procedure for the diagnosis of brain lesions and will likely gain clinical importance. Since FBSB procedures comprise a variety of imaging and sampling methods, it is necessary to compare the safety and effectiveness of individual techniques.Entities:
Mesh:
Year: 2018 PMID: 30352066 PMCID: PMC6198960 DOI: 10.1371/journal.pone.0205772
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Positioning of the patient in the iMRI-scanner and setup of coils.
The head of the patient with mounted frame and localizers is placed into the lower half of the 4-channel send/receive coil (double arrow). Due to the fact that the standard head coil (upper and lower part) does not accommodate the whole package, a flexible coil is used as upper half (black single arrow). This coil assembly was tested extensively prior to commissioning of the iMRI and yields good signal-to-noise ratios.
Fig 2Setup of anesthesia equipment in the iMRI scanner.
The MR-capable ventilator (Dräger Fabius MRI, Drägerwerke, Lübeck, Germany) is positioned outside the 30 mT area (dark line) while the monitoring hardware has to be kept outside the 20 mT area (light yellow line).
Demographics of subjects in both study cohorts.
| iMRI (n = 500) | Control (n = 100) | p | ||||
|---|---|---|---|---|---|---|
| 06/2009–03/2016 | 04/2008–06/2009 | |||||
| Range | 1–89 | 2–83 | .26 | |||
| Mean | 55.4 | 53.1 | ||||
| Median | 58 | 55 | ||||
| Female | 231 | 46% | 49 | 49% | .66 | |
| Male | 269 | 54% | 51 | 51% | ||
| 0 | 255 | 51% | 47 | 47% | .53 | |
| 1 | 89 | 18% | 16 | 16% | ||
| 2 | 85 | 17% | 19 | 19% | ||
| 3 | 45 | 9% | 15 | 15% | ||
| 4 | 22 | 4% | 3 | 3% | ||
| 5 | 4 | 1% | 0 | 0% | ||
| Range | 0–35 | 0–15 | .09 | |||
| Median | 0 | 2 | ||||
| I | 33 | 7% | 10 | 10% | .17 | |
| II | 267 | 53% | 47 | 47% | ||
| III | 188 | 38% | 43 | 43% | ||
| IV | 12 | 2% | 0 | 0% | ||
| V | 0 | 0% | 0 | 0% | ||
a Independent samples t-test
b Fisher’s exact test
cMann-Whitney U-test
mRS = modified Rankin Scale. mNIHSS = modified National Institute of Health Stroke Scale. ASA = American Society of Anesthesiologists Physical Status Classification System. iMRI = intraoperative MRI
Location of biopsy targets.
| Target location | iMRI | Control | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Frontal lobe | 164 | 32.8% | 37 | 37.0% | |
| Temporal lobe | 78 | 15.6% | 22 | 22.0% | |
| Parietal lobe | 25 | 5.0% | 9 | 9.0% | |
| Occipital lobe | 79 | 15.8% | 8 | 8.0% | |
| Insula | 11 | 2.2% | 3 | 3.0% | |
| Basal ganglia | 43 | 8.6% | 10 | 10.0% | |
| Diencephalon | 39 | 7.8% | 6 | 6.0% | |
| Mesencephalon | 7 | 1.4% | 1 | 1.0% | |
| Pons | 28 | 5.6% | 1 | 1.0% | |
| Cerebellum | 23 | 4.6% | 2 | 2.0% | |
| Medulla oblongata | 3 | 0.6% | 1 | 1.0% | |
iMRI = intraoperative MRI
Fig 3Procedure duration stratified by imaging modality.
The duration of the procedures (time spent in the stereotactic frame) was significantly influenced by the imaging modality used to acquire the stereotactic dataset (One-way ANOVA, p < .000). Post-hoc testing (LSD-Bonferroni) showed significant differences between each individual imaging modality with exception of the CT/MRI pair. Procedures performed with intraoperative CT (iCT) required the least amount of time (median 110 min) followed by iMRI-based biopsies in second place (median 120 min). Imaging performed outside the OR (CT and MRI) considerably increased overall procedure time.
Postoperative imaging, hematoma and neurologic status in the iMRI cohort.
| iMRI | Postoperative deterioration | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| Death | Major | Minor | None | |||||
| No | 0 | 0 | 2 | 374 | ||||
| Yes | No | 0 | 8 | 7 | 95 | |||
| Yes | 3 | 4 | 0 | 7 | ||||
iMRI = intraoperative MRI
Postoperative imaging, hematoma and neurologic status in the control cohort.
| Control | Postoperative deterioration | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| Death | Major | Minor | None | |||||
| No | 0 | 0 | 2 | 83 | ||||
| Yes | No | 0 | 1 | 1 | 11 | |||
| Yes | 0 | 0 | 0 | 2 | ||||
iMRI = intraoperative MRI
Summary of complications.
| iMRI | Control | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| n | % | 95% C.I. | n | % | 95% C.I. | p | |||
| lower | upper | lower | upper | ||||||
| 0.12% | 1.74% | 0.00% | 3.62% | .99 | |||||
| 1.25% | 4.15% | 0.03% | 5.45% | .70 | |||||
| 0.83% | 3.39% | 0.62% | 8.52% | .43 | |||||
| 0.44% | 2.59% | 0.00% | 3.62% | .62 | |||||
| 0.00% | 0.74% | 0.00% | 7.04% | .99 | |||||
| 1.84% | 5.14% | 1.10% | 9.93% | .99 | |||||
iMRI = intraoperative MRI
*Clopper-Pearson
**two-sided Fisher’s exact test